首页> 外文期刊>World Journal of Gastroenterology >New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.
【24h】

New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.

机译:使用Amplicor GT HCV MONITOR test v2.0进行的丙型肝炎病毒基因型和病毒载量的新组合测试。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To develop a new sensitive and inexpensive hepatitis C virus (HCV) combination test (HCV Guideline test) that enables the determination of HCV genotypes 1, 2 and 3, and simultaneous determination of HCV viral load using commercial Amplicor GT HCV MONITOR test v2.0 (microwell version). METHODS: The HCV Guideline test used the PCR product generated in commercial Amplicor GT HCV Monitor test v2.0 for viral load measurement using microwell plate version of Amplicor HCV Monitor and also captured on separate plates containing capture probes and competitive oligonucleotide probes specific for HCV genotypes 1, 2 and 3, The HCV genotype was subsequently determined using the biotin-labeled PCR product and five biotin-labeled HCV-specific probes. RESULTS: The sensitivity of the HCV Guideline test was 0.5 KIU/mL. Specificity of the HCV Guideline test was confirmed by direct sequencing of HCV core region and molecular evolutionary analyses based on a panel of 31 samples. The comparison of the HCV Guideline test and an in-house HCV core genotyping assay using 252 samples from chronic hepatitis C patients indicated concordant results for 97.2% of samples (59.5% genotype 1, 33.7% genotype 2, 6.0% genotype 3, and 0.8% mixed genotypes). Similarly, the HCV Guideline test showed concordance with a serological test, and the serological test failed to assign any serotype in 12.7% of the samples, indicating a better sensitivity of the HCV Guideline test. CONCLUSION: Clinically, both viral load and genotypes (1, 2 and 3) have been found to be major predictors of antiviral therapy outcome regarding chronic hepatitis C based on guidelines and they are, in normal circumstances, performed as separate stand-alone assays. The HCV Guideline test is a useful method for screening large cohorts in a routine clinical setting for determining the treatment regimen and for predicting the outcome of antiviral therapy of chronic hepatitis C.
机译:目的:开发一种新的敏感且廉价的丙型肝炎病毒(HCV)组合测试(HCV准则测试),从而能够确定HCV基因型1、2和3,并使用商业Amplicor GT HCV MONITOR测试v2同时确定HCV病毒载量.0(微孔版)。方法:HCV指南测试使用商业Amplicor GT HCV Monitor test v2.0中生成的PCR产物,使用Amplicor HCV Monitor的微孔板版本进行病毒载量测量,并且还捕获在单独的板上,其中包含捕获探针和针对HCV基因型的竞争性寡核苷酸探针参照图1、2和3,随后使用生物素标记的PCR产物和五种生物素标记的HCV特异性探针确定HCV基因型。结果:HCV指南测试的灵敏度为0.5 KIU / mL。 HCV指南测试的特异性通过对HCV核心区域的直接测序和基于一组31个样品的分子进化分析得到证实。 HCV指南测试与使用252例慢性丙型肝炎患者的内部HCV核心基因型分析的比较表明,97.2%的样本(59.5%的基因型1、33.7%的基因型2、6.0%的基因型3和0.8)的结果一致。 %混合基因型)。同样,HCV指南测试显示与血清学测试一致,血清学测试未能在12.7%的样品中分配任何血清型,表明HCV指南测试具有更高的敏感性。结论:在临床上,根据指南,病毒载量和基因型(1、2和3)均是慢性丙型肝炎抗病毒治疗结局的主要预测指标,在正常情况下,它们应作为独立的独立测定进行分析。 HCV指南测试是一种有用的方法,可用于在常规临床环境中筛选大型队列,以确定治疗方案和预测慢性丙型肝炎的抗病毒治疗结果。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号